NCT04621929 - Obesity and Uric Acid Stones Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2021

Primary Completion Date

November 14, 2024

Study Completion Date

November 14, 2024

Conditions

ObesityUric Acid StonesType 2 Diabetes Mellitus in ObesePre-Diabetes

Interventions

DRUG

Phentermine / Topiramate Oral Product

All participants in the experimental group will receive oral generic tablet phentermine (18.75 or 37.5 mg dose) and topiramate (daily 100 mg or 150 mg dose)

COMBINATION_PRODUCT

Citrate Salts, Allopurinol, Diet

Control participants will complete initial visit requirements and study enrollment and will be maintained on their current therapy.

Trial Locations (1)

32610

University of Florida, Gainesville

All Listed Sponsors

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Florida

OTHER